Covalon Technologies (Covalon Technologies) Debt-to-Equity

: 0.08 (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

Covalon Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.48 Mil. Covalon Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.55 Mil. Covalon Technologies's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $13.17 Mil. Covalon Technologies's debt to equity for the quarter that ended in Dec. 2023 was 0.08.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Covalon Technologies's Debt-to-Equity or its related term are showing as below:

CVALF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.08 Med: 0.13 Max: 2.49
Current: 0.08

During the past 13 years, the highest Debt-to-Equity Ratio of Covalon Technologies was 2.49. The lowest was 0.08. And the median was 0.13.

CVALF's Debt-to-Equity is ranked better than
63.19% of 1073 companies
in the Biotechnology industry
Industry Median: 0.14 vs CVALF: 0.08

Covalon Technologies Debt-to-Equity Historical Data

The historical data trend for Covalon Technologies's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Array ( [0] => - [1] => - [2] => - [3] => - [4] => - [5] => 1.21 [6] => 2.30 [7] => 0.08 [8] => 0.09 [9] => 0.08 )

Covalon Technologies Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Debt-to-Equity

1.21

2.30

0.08

0.09

0.08

Covalon Technologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity																0.09	0.08	0.08	0.08	0.08

Competitive Comparison

For the Biotechnology subindustry, Covalon Technologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Covalon Technologies Debt-to-Equity Distribution

For the Biotechnology industry and Healthcare sector, Covalon Technologies's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Covalon Technologies's Debt-to-Equity falls into.

Covalon Technologies Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Covalon Technologies's Debt to Equity Ratio for the fiscal year that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.475	+	0.679)	/	13.889
	=	0.08

Covalon Technologies's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.477	+	0.549)	/	13.171
	=	0.08

Covalon Technologies (OTCPK:CVALF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Covalon Technologies Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Covalon Technologies's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Covalon Technologies (Covalon Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Covalon Technologies Ltd (OTCPK:CVALF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

COV:Canada

Address

1660 Tech Avenue, Unit 5, Mississauga, ON, CAN, L4W 5S7

Website

https://www.covalon.com

Covalon Technologies Ltd is principally engaged in the business of developing, licensing, and selling medical technologies. The company develops advanced wound care line which is designed for the treatment of a wide range of wounds; and infection prevention products such as MediClear PreOp which is a breathable, transparent, self-adhesive silicone barrier film that conforms to the contours of the body. It also develops perioperative care products. The company generates its revenue through development contracts, licensing agreements, and distribution contracts, and sales.